Equity Profile

PCVX

Vaxcyte, Inc.

Health CareBiotechnology$6.8B

Aug5Wed

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EDT

Company Snapshot

Vaxcyte, Inc. (PCVX) is a biotechnology company focused on developing vaccines to prevent infectious diseases....

Key Metrics to Watch

EPS

Earnings per share (EPS) is a key indicator of the company's profitability and financial health.

N/A

Revenue

Revenue growth will indicate the company's ability to expand its market presence and product acceptance.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

PCVX Q2-2026 Earnings Preview

Context

Company Snapshot

Vaxcyte, Inc. (PCVX) is a biotechnology company focused on developing vaccines to prevent infectious diseases. With a market cap of $7 billion, it operates in the health care sector, which is increasingly important as global health challenges continue to rise.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

25%

Avg EPS Surprise

-39.32%

Avg Stock Reaction

-0.06%

Last Quarter Recap

In Q1-2026, Vaxcyte reported an EPS of -$2.30, which was worse than the expected -$1.85. The stock reacted positively, gaining 2.62% the following day.

Management Promises & Guidance

Focus on advancing vaccine candidates.
Commitment to improving operational efficiency.
Plans to enhance partnerships for broader distribution.

Expectations

Wall Street Expectations

Investors are cautious ahead of the earnings report, especially given the company's recent earnings misses. There is uncertainty about how the company will address its ongoing losses.

Bull Case

If Vaxcyte can demonstrate significant progress in its vaccine pipeline and show improved financial metrics, it could lead to a strong positive reaction from the market.

Bear Case

Should the company report larger-than-expected losses or provide weak guidance on its vaccine development, it could lead to a sharp decline in the stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the current status of Vaxcyte's vaccine candidates and their expected timelines?

The market will closely watch for updates on vaccine development as this will significantly impact future revenue and growth potential.

How does Vaxcyte plan to address its ongoing financial losses?

Investors need clarity on the company's strategy to improve profitability, which is crucial for maintaining investor confidence.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for Vaxcyte's vaccine candidates to gain traction in the market, especially given the increasing demand for innovative health solutions.

Supporting Evidence

The options market is pricing in a 22.18% move, indicating that traders expect significant volatility, which may not align with the Street's conservative outlook.

Vaxcyte's recent stock performance has shown resilience despite earnings misses, suggesting underlying strength.

Key Risk

If the company provides strong updates on vaccine candidates, it could shift market sentiment significantly.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core debate this quarter revolves around the company's ability to turn its vaccine development efforts into financial success.

Bull Confirmed If

Demonstrating progress in vaccine development with at least one candidate entering advanced trials.

Bear Confirmed If

Reporting a larger loss than expected or failing to provide a clear path to profitability.

Pre-Earnings Positioning

Options Market

Implied Move

±22.18%

Historical Avg

±1.8%

Pricing rich

The options market is pricing in a significant move, suggesting that traders expect volatility around the earnings report.

Options are pricing ±22.2% while PCVX has averaged ±1.8% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.5%

30d HV

49.6%

Calls (100)P/C Ratio: 0.12Puts (7K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 3.6%, with a raw directional average of -1.3% (modestly negative historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Vaxcyte beats expectations, history suggests the stock could see a modest increase, confirming the potential for future growth.

In-Line / Cautious

If results are in line with expectations, the stock may remain stable, but cautious commentary could lead to volatility.

Miss

If the company misses expectations, history suggests a potential decline in stock price, reflecting investor disappointment.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the progress of vaccine candidates and any upcoming clinical trial phases.
2Management's strategy for addressing financial losses and improving profitability.
3Any new partnerships or collaborations that could enhance distribution capabilities.
4Insights into market demand for Vaxcyte's vaccine products.
5Future guidance on revenue expectations and operational goals.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug3

ONBMO

ON Semiconductor Corporation

PreviewView

Aug3

LBMO

Company Snapshot

Vaxcyte, Inc. (PCVX) is a biotechnology company focused on developing vaccines to prevent infectious diseases....

Key Metrics to Watch

EPS

Earnings per share (EPS) is a key indicator of the company's profitability and financial health.

N/A

Revenue

Revenue growth will indicate the company's ability to expand its market presence and product acceptance.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

PCVX Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

25%

Avg EPS Surprise

-39.32%

Avg Stock Reaction

-0.06%

Last Quarter Recap

In Q1-2026, Vaxcyte reported an EPS of -$2.30, which was worse than the expected -$1.85. The stock reacted positively, gaining 2.62% the following day.

Management Promises & Guidance

Focus on advancing vaccine candidates.
Commitment to improving operational efficiency.
Plans to enhance partnerships for broader distribution.

Expectations

Wall Street Expectations

Investors are cautious ahead of the earnings report, especially given the company's recent earnings misses. There is uncertainty about how the company will address its ongoing losses.

Bull Case

If Vaxcyte can demonstrate significant progress in its vaccine pipeline and show improved financial metrics, it could lead to a strong positive reaction from the market.

Bear Case

Should the company report larger-than-expected losses or provide weak guidance on its vaccine development, it could lead to a sharp decline in the stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the current status of Vaxcyte's vaccine candidates and their expected timelines?

The market will closely watch for updates on vaccine development as this will significantly impact future revenue and growth potential.

How does Vaxcyte plan to address its ongoing financial losses?

Investors need clarity on the company's strategy to improve profitability, which is crucial for maintaining investor confidence.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for Vaxcyte's vaccine candidates to gain traction in the market, especially given the increasing demand for innovative health solutions.

Supporting Evidence

The options market is pricing in a 22.18% move, indicating that traders expect significant volatility, which may not align with the Street's conservative outlook.

Vaxcyte's recent stock performance has shown resilience despite earnings misses, suggesting underlying strength.

Key Risk

If the company provides strong updates on vaccine candidates, it could shift market sentiment significantly.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core debate this quarter revolves around the company's ability to turn its vaccine development efforts into financial success.

Bull Confirmed If

Demonstrating progress in vaccine development with at least one candidate entering advanced trials.

Bear Confirmed If

Reporting a larger loss than expected or failing to provide a clear path to profitability.

Pre-Earnings Positioning

Options Market

Implied Move

±22.18%

Historical Avg

±1.8%

Pricing rich

The options market is pricing in a significant move, suggesting that traders expect volatility around the earnings report.

Options are pricing ±22.2% while PCVX has averaged ±1.8% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.5%

30d HV

49.6%

Calls (100)P/C Ratio: 0.12Puts (7K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Vaxcyte beats expectations, history suggests the stock could see a modest increase, confirming the potential for future growth.

In-Line / Cautious

If results are in line with expectations, the stock may remain stable, but cautious commentary could lead to volatility.

Miss

If the company misses expectations, history suggests a potential decline in stock price, reflecting investor disappointment.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the progress of vaccine candidates and any upcoming clinical trial phases.
2Management's strategy for addressing financial losses and improving profitability.
3Any new partnerships or collaborations that could enhance distribution capabilities.
4Insights into market demand for Vaxcyte's vaccine products.
5Future guidance on revenue expectations and operational goals.